Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2B3-201 in Healthy Volunteers and MS Patients
NCT02048358Phase 1Terminated
- Sponsor
- 2-BBB Medicines
- Start
- Nov 2013
- Primary completion
- Jan 2015
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ENX-201 in multiple sclerosis (MS) (9 arms), sponsored by 2-BBB Medicines. Primary endpoints: Number of subjects with adverse events at 3 weeks, Maximum Plasma Concentration at 3 weeks and 4 more. Started Nov 2013; status: terminated.
02
Drugs
ENX-201
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02048358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02048358.